Syneron Medical (Nasdaq: ELOS ) is expected to report Q4 earnings on Feb. 12. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Syneron Medical's revenues will increase 15.7% and EPS will wither -280.0%.
The average estimate for revenue is $70.6 million. On the bottom line, the average EPS estimate is $0.09.
Last quarter, Syneron Medical logged revenue of $60.1 million. GAAP reported sales were 5.5% higher than the prior-year quarter's $57.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.03. GAAP EPS were -$0.06 for Q3 against -$1.14 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 53.2%, 260 basis points better than the prior-year quarter. Operating margin was -3.6%, 6,130 basis points better than the prior-year quarter. Net margin was -3.8%, 6,660 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $261.5 million. The average EPS estimate is $0.19.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 706 members out of 740 rating the stock outperform, and 34 members rating it underperform. Among 213 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 207 give Syneron Medical a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Syneron Medical is buy, with an average price target of $17.38.
Is Syneron Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.